Unknown

Dataset Information

0

Interferon-complement loop in transplant-associated thrombotic microangiopathy.


ABSTRACT: Transplant-associated thrombotic microangiopathy (TA-TMA) is an important cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The complement inhibitor eculizumab improves TA-TMA, but not all patients respond to therapy, prompting a search for additional targetable pathways of endothelial injury. TA-TMA is relatively common after HSCT and can serve as a model to study mechanisms of tissue injury in other thrombotic microangiopathies. In this work, we performed transcriptome analyses of peripheral blood mononuclear cells collected before HSCT, at onset of TA-TMA, and after resolution of TA-TMA in children with and without TA-TMA after HSCT. We observed significant upregulation of the classical, alternative, and lectin complement pathways during active TA-TMA. Essentially all upregulated genes and pathways returned to baseline expression levels at resolution of TA-TMA after eculizumab therapy, supporting the clinical practice of discontinuing complement blockade after resolution of TA-TMA. Further analysis of the global transcriptional regulatory network showed a notable interferon signature associated with TA-TMA with increased STAT1 and STAT2 signaling that resolved after complement blockade. In summary, we observed activation of multiple complement pathways in TA-TMA, in contrast to atypical hemolytic uremic syndrome (aHUS), where complement activation occurs largely via the alternative pathway. Our data also suggest a key relationship between increased interferon signaling, complement activation, and TA-TMA. We propose a model of an "interferon-complement loop" that can perpetuate endothelial injury and thrombotic microangiopathy. These findings open opportunities to study novel complement blockers and combined anti-complement and anti-interferon therapies in patients with TA-TMA and other microangiopathies like aHUS and lupus-associated TMAs.

SUBMITTER: Jodele S 

PROVIDER: S-EPMC7094010 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Interferon-complement loop in transplant-associated thrombotic microangiopathy.

Jodele Sonata S   Medvedovic Mario M   Luebbering Nathan N   Chen Jenny J   Dandoy Christopher E CE   Laskin Benjamin L BL   Davies Stella M SM  

Blood advances 20200301 6


Transplant-associated thrombotic microangiopathy (TA-TMA) is an important cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The complement inhibitor eculizumab improves TA-TMA, but not all patients respond to therapy, prompting a search for additional targetable pathways of endothelial injury. TA-TMA is relatively common after HSCT and can serve as a model to study mechanisms of tissue injury in other thrombotic microangiopathies. In this work, we performed t  ...[more]

Similar Datasets

2020-03-30 | GSE134979 | GEO
| S-EPMC8315095 | biostudies-literature
| S-EPMC7575444 | biostudies-literature
| S-EPMC8023217 | biostudies-literature
| S-EPMC6945915 | biostudies-literature
| PRJNA556908 | ENA
| S-EPMC5728339 | biostudies-literature
| S-EPMC7256332 | biostudies-literature
| S-EPMC7726817 | biostudies-literature
| S-EPMC8023184 | biostudies-literature